Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Conclusions: CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.PMID:38420695 | DOI:10.1080/13696998.2024.2319458

Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Hussain A Al-Omar Hind S Almodaimegh Abubker Omaer Lamya M Alzubaidi Bandar Al-Harbi Ibtisam Al-Harbi Mohamed Hassan Abdulmohsen Abanumay Omar Akhtar Source Type: research